Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Evaluation of olfactory dysfunction in neurodegenerative diseases.
Epstein-Barr virus Peptide Presented by HLA-E is Predominantly Recognized by CD8(bright) Cells in multiple Sclerosis Patients.
FDA approves clinical trial of TDI-132 (Gilenya) in ALS patients
The Impact of Lesion In-Painting and Registration Methods on Voxel-Based Morphometry in Detecting Regional Cerebral Gray Matter Atrophy in Multiple Sclerosis.
Limb Apraxia in Multiple Sclerosis: Prevalence and Impact on Manual Dexterity and Activities of Daily Living.
Breastfeeding is associated with lower risk for multiple sclerosis.
Patient's Perspective: Hard Lessons from a Long Hospital Stay.
Patients feeling severely affected by multiple sclerosis: How do patients want to communicate about end-of-life issues?
The unwavering commitment of regulatory T cells in the suppression of autoimmune encephalomyelitis: Another aspect of immune privilege in the CNS.
Risk of vascular disease in patients with multiple sclerosis: a review.
Personalized Medicine in Neurodegenerative Diseases: How Far Away?
The attributable burden of panic disorder in the impairment of quality of life in a national survey in Italy.
Cannabinoid pharmacology: the first 66 years.
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients.
Long-term TENS treatment decreases cortical motor representation in multiple sclerosis.
Modeling the variability in brain morphology and lesion distribution in multiple sclerosis by deep learning.
Substance Name: Dronabinol
160 Surgical outcomes of trigeminal neuralgia in patients with multiple sclerosis.
Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study.
Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses.
Twin studies and the heritability of MS: a conclusion.
Amelioration of experimental autoimmune encephalomyelitis by anatabine.
The Role of Demyelination in Neuromyelitis Optica Damage: Diffusion-Tensor MR Imaging Study.
Can we overcome the 'clinico-radiological paradox' in multiple sclerosis?
Pages
« first
‹ previous
…
176
177
178
179
180
181
182
183
184
…
next ›
last »